Secondary Logo

Journal Logo


JAIDS Journal of Acquired Immune Deficiency Syndromes: April 2011 - Volume 56 - Issue - p 21-33
doi: 10.1097/01.qai.0000397292.87679.2b
Speaker Schedule
Back to Top | Article Outline


Monday, October 4, 2010

10:30 a.m. Satellite Symposium

Back to Top | Article Outline

Fogarty Scholars Forum

Chair:William A. Blattner, M.D. - Institute of Human Virology

Back to Top | Article Outline

Italian Society for Medical Virology (SIVIM) Symposium

Back to Top | Article Outline

HIV in Italy

Chairs:Maria C. Re, Ph.D. - University of Bologna andAdriano Lazzarin, M.D. - Università Vita-Salute San


1:00 p.m. Introduction: Giuseppe Ippolito, M.D., Scientific director - National Institute for Infectious diseases

HIV/AIDS in Italy: Divers and Dynamics

1:05 p.m. Paola Cinque, M.D. - San Raffaele Scientific Institute

Immunoactivation and HIV

1:23 p.m. Gabriella D'Ettorre, M.D. - La Sapienza University 102

HIV-DNA and Therapy

1:41 p.m.  Filippo Canducci, M.D. - Vita-Salute San Raffaele University

Viral Fitness and Therapy of HIV Infection

2:00 p.m. Mauro Pistello, Ph.D. - University of Pisa

Lessons Learned from the Feline Immunodeficiency Virus/AIDS Model

Back to Top | Article Outline

Special Symposium on HIV and Malignant Disease in Africa

Chairs: Mauro Moroni, M.D. - Ospedale Niguarda Ca' Granda, Umberto Tirelli, M.D. - National CancerInstitute and Joe O'Neill - University of Maryland, Baltimore

2:18 p.m. William Blattner, M.D. - Institute of Human Virology 105

HIV and Viral Associated Malignancies

2:36 p.m.  Clement Adebamowo, D.Sc., M.D., FWACS, FACS - Institute of Human Virology 106

Cancer Research in Africa

2:54 p.m. Annie Sasco, M.D., Ph.D. - Victor Ségalen Bordeaux 2 University 107

Cancer and HIV in Sub-Saharan Africa: Not Exactly as in the North

3:12 p.m. Max Essex, DVM, Ph.D. - Harvard University School of Public Health 108

HIV-1C of Southern Africa: Why is the Virus More Fit?

3:30 p.m. Sam Mbulaiteye, M.D. - National Cancer Institute 109

Epidemiology of AIDS-Related Malignancies: Current Knowledge andOpportunities for Etiological Studies in the Setting of HIV Treatment Programs

Back to Top | Article Outline

Roundtable: Research Needs and Challenges in Africa and the Developing World

Moderator: Joe O'Neill, M.D - University of Maryland, Baltimore

William Blattner, M.D. - Institute of Human Virology, Clement Adebamowo, D.Sc., M.D., FWACS, FACS

- Institute of Human Virology, Annie Sasco, M.D., Ph.D. - Victor Ségalen Bordeaux 2 University, Max

Essex, DVM, Ph.D. - Harvard University School of Public Health, Sam Mbulaiteye, M.D. - National Cancer


4:00 p.m. ADJOURN

Back to Top | Article Outline

Formal Opening Ceremony, Welcome and Reception

6:00 p.m. Refreshments

6:30 p.m. Welcome Remarks by Robert C. Gallo

 Kathleen kennedy Townsend, Chair IHV Board of Advisors

 Ferruccio fazio, Minister of Health

 Giuseppe Scopelliti, Governor of Calabria

 Giovanni Latorre, Ph.D, Rector - University of Calabria

7:00 p.m. Robert C. Gallo, M.D. - Institute of Human Virology Key Problems in HIV Research

7:15 p.m. Light Dinner: Speakers, participants, and guests are invited to attend.

Back to Top | Article Outline

Tuesday, October 5, 2010

Insights from Basic Science 1

Chairs:Giuseppe Teti, M.D. - University of Messina Medical School and Roberto Accolla, M.D. - University of


9:00 a.m.Andrea Cerutti, M.D. - Weill Cornell Medical College 110

Nef-Trafficking Intercellular Highways for HIV Evasion of Antibody Production

9:18 a.m.Suzanne Gartner, Ph.D. - Institute of Human Virology 111

Generation of Cells Within Human Nurse Macrophages and ConsequencesFollowing HIV Infectio

9:36 a.m.Guido Poli, M.D. - San Raffaele Scientific Institute 112

Multifaceted Infection and Replication ofHIV-1 in Human Macrophages

9:54 a.m.  Warner Greene, M.D., Ph.D. - Gladstone Institute of Virology and Immunology  113

Murder on the HIV Express: Insights into How CD4 T Cells are Killed in Lymphoid Tissues

10:12 a.m. Leonid Margolis, Ph.D. - National Institutes of Health 114

HIV Interactions With Other Viruses in Human Tissues as Determinantsof HIV Infection

10:30 a.m. William Hall, M.D., Ph.D. - University College dublin 115

HIV-1 Rev and Regulation of Rev Nucleo-Cytoplasmic Shuttling

20 minutes BREAK

Back to Top | Article Outline

Special Lecture

10:47 a.m. Zeng Yi, Ph.D. - Institute for Viral disease

Prevention and Control Study on Therapeutic Vaccine for AIDS Treatment

Back to Top | Article Outline

Insights from Basic Science 2

Chairs:Umberto Bertazzoni, Ph.D. - University of Verona and Vittorio Colizzi, M.D., Ph.D. - University of

Rome, Tor Vergata

11:10 a.m. John Moore, Ph.D. - Weill Cornell Medical College 118

Inhibiting CCR5 in vitro and in vivo

11:28 a.m. Mario Stevenson, Ph.D. - University of Massachusetts Medical Center 119

Viral Attack and Cellular Defense: The Role of Cellular Restrictions in theBiology of Primate Lentiviruses

11:46 a.m. Alain Lafeuillade, M.D. - Chalucet Hospital 120

HIV Persistence Challenging Therapeutic Success

12:04 p.m. Marie-Lise Gougeon, Ph.D. - Institute Pasteur 121

Contributions of Innate Immunity to the Establishment of HIV Reservoirin DC: Role for DC:NK Cross-Talk

12:22 p.m. Monsef Benkirane, Ph.D. - Institute of Human Genetics 122

Interplay Between HIV Replication and MicroRNAs

12:40 p.m. Eric Verdin, M.D. - Gladstone Institute of Virology and Immunology 123

Molecular Mechanisms of HIV Latency

12:58 p.m.  LUNCH

2:30 p.m.  Institute of Human Virology Lifetime Scientific Achievement Award 2010

 Robert C. Gallo, M.D. - Institute of Human Virology

Introduction ofRino Rappuoli, Ph.D., 2010 Award Recipient

Back to Top | Article Outline

Special Seminar

 Rino Rappuoli, Ph.D.

Novartis Vaccines and Diagnostics

3:00 p.m.  Selected Abstracts for Oral Presentation

Chairs:Fernando Aiuti, M.D. - University of Rome and Nancy Miller, M.D. - National Institute of Allergy and

Infectious Diseases

3:05 p.m. Alfredo Garzino-demo, Ph.D. - Institute of Human Virology 124

CCR6 Ligands Inhibit HIV in Highly Susceptible CD4+CCR6+ T Cellsby Inducing APOBEC3G Expression

3:12 p.m. Giulia della Chiara, Ph.D. - San Raffaele Scientific Institute 125

Naturally c-Terminally Truncated STAT5 (STAT5Δ): A Negative Controllerof HIV-1 Transcription and Expression

3:19 p.m. Marina Lusic, Ph.D. - San Raffaele Scientific Institute 126

PML Nuclear Bodies Determine the Repressive Environment and RestrictViral Gene Expression in Primary Human Lymphocytes

3:26 p.m. Elisa Vicenzi - San Raffaele Scientific Institute 127

Characterization of Tripartite-Motif (TRIM) 22-Mediated Inhibition ofHIV-1 Transcription

3:33 p.m. Olga Latinovic, Ph.D. - Institute of Human Virology 128

Suppression of CCR5 Density as a Novel Way to Enhance the Anti-HIV Activityof Fusion Inhibitors and CCR5 Antagonists

3:40 p.m. Apostolos Rizos, Ph.D. - University of Crete 129

HIV and Immune System Deregulation

3:47 p.m. Ming Zeng, Ph.D. - University of Minnesota 130

Lymphoid Tissue Niche Damage in SIV Infection Depletes Naïve T Cells

3:54 p.m. A.J. Smith, Ph.D. - University of Minnesota 131

The Role of Chitinase 3-Like-1 in the Pathological Deposition of Collagenin Lymphatic Tissue During HIV-1Infection

4:01 p.m. Michael Thomson, Ph.D. - Institute de Salud Carlos III 132

Identification of New Patterns of Splice Site Usage by Transcriptsof HIV-1 Primary Isolates of Diverse Subtypes

4:08 p.m. Ramesh Akkina, Ph.D. - Colorado State University 133

Aptamer-siRNA Chimera Therapy Suppresses HIV-1 Viral Loads andProtects From CD4 TCell Loss in Humanized (RAG-hu) Mice

4:15 p.m. Cristiana Cairo, Ph.D. - Institute of Human Virology 134

Population Level Variations in the Baseline Value for Vδ2 T Cells andImplications for the Study of Infectious Diseases

4:22 p.m.  Natalia freund, Ph.D. - Tel Aviv University 135

Reconstitution of Conformational B-Cell Epitopes Using Combinatorial Con former Libraries

4:29 p.m.  Chiara Orlandi, Ph.D. - University of Insubria 136

HTLV-2 Tax-2 Transactivator Increases the Expression and the Functionof its Inhibitor CIITA, the Master Regulator of HLA-II Gene Transcription

4:36 p.m. ADJOURN

6:00 p.m. Aperitivo

8:30 p.m.  Lifetime Achievement Gala Banquet and Awards Ceremony

Location: Sunshine Club Hotel Ballroom

All speakers, participants, and guests are invited to attend.

Back to Top | Article Outline

Wednesday, October 6, 2010

HIV Vaccine Part 1: Challenges to HIV Vaccine Development

Chairs:Robert C. Gallo, M.D - Institute of Human Virology and Franco Buonaguro, M.D - National Cancer

Institute, Fond Pascale

9:00 a.m.  Robert C. Gallo, M.D. - Institute of Human Virology

Introduction - The Key Basic Science Issues in Developing an HIV Vaccine

9:18 a.m.  Nelson L. Michael, M.D., Ph.D. - Walter Reed Army Institute of Research 138

Building on the Results of the RV144 Prime Boost HIV Vaccine Efficacy Study

9:36 a.m.  Jay Berz of sky, M.D., Ph.D. - National Cancer Institute 139

A Novel Nanoparticle Approach to Induce Colorectal and VaginalMucosal Immunity

9:54 a.m.  Mark J. Newman, Ph.D.-GeoVax Inc. 140

Induction of Efficacious Immune Responses Using Heterologous PrimeBoost Regimens of Recombinant DNA and MVA HIV Vaccines and GM-CSFas the Adjuvant

Back to Top | Article Outline

HIV Vaccine Part 2: Antibody Response to HIV Env

Chairs:Alan Bernstein, OC, Ph.D., FRSC - Global HIV Vaccine Enterprise and Massimo Clementi, M.D.

- Università Vita-Salute San Raffaele

10:12 a.m.  Leonidas Stamatatos, Ph.D. - Seattle Biomedical Research Institute 141

Characteristics of the Earliest Cross-Neutralizing Antibody Response to HIV-1

10:50 a.m. Jonathan Gershoni, Ph.D. - Tel Aviv University 142

Steps Toward Epitope-Based Vaccines

11:08 a.m. Julie Overbaugh, Ph.D. - fred Hutchinson Cancer Research Center 143

HIV Transmission: The Role of Neutralizing Antibodies

11:26 a.m. Anthony DeVico, Ph.D. - Institute of Human Virology 144

Protection Against Heterologous SHIV Challenge Afforded by Immunization of Rhesus Macaques With a Subunit Immunogen that Mimics a TransitionState HIV Envelope Structure

Back to Top | Article Outline

Special Lecture

11:44 a.m.  Hans Wigzell, M.D., director of the Center for Medical Innovations -Karolinska Institute

12:02 p.m. Roundtable: What Has Been Learned from Clinical Trials

Moderator:Alan Bernstein, OC, Ph.D., FRSC - Global HIV Vaccine Enterprise

Gary Nabel, M.D., Ph.D. - National Institutes of Health; Nelson L. Michael, M.D., Ph.D. - Walter Reed Army

Institute of Research; Robert C. Gallo, M.D. - Institute of Human Virology; Jim Tartaglia, Ph.D. - Sanofi

Pasteur, Ltd.; Hans Wigzell, M.D., Director of the Center for Medical Innovations - Karolinska Institute; and

David Montefiori, Ph.D. - Duke University

Back to Top | Article Outline

HIV Vaccine Part 3: Alternatives for Vaccine Delivery

Chairs:Giorgio Palú, M.D. - University of Padua and Carlo F. Perno, M.D. - University of Rome Tor Vergata

12:30 p.m. Gunnel Biberfeld, M.D., Ph.D. - karolinska Institutet 146

Strong and Broad Immunogenicity of a Multigene, Multiclade HIV-1 DNAPrime MVA Boost Vaccine Regimen Among Healthy Tanzanian Volunteers

12:48 p.m.  Gary Nabel, M.D., Ph.D. - National Institutes of Health 147

Rational Design of Envelope Surface Identifies Broadly NeutralizingHuman Monoclonal Antibodies to HIV-1

1:06 p.m. Jim Tartaglia, Ph.D. - Sanofi Pasteur, Ltd. 148

Moving Forward From RV144: An Industrial Perspective

1:30 p.m.  LUNCH

3:00 p.m. Dan Barouch, M.D., Ph.D. - Beth Israel deaconess Medical Center 149

Novel Vectors and Antigens for a Next Generation HIV-1 Vaccine

3:18 p.m. Genoveffa Franchini, Ph.D. - National Cancer Institute 150

Retooling the Macaque Model as a Necessary Step to Evaluatethe Relative Efficacy of Vaccines for HIV

3:36 p.m. Giuseppe Pantaleo, M.D. - Centre Hospitalier Universitaire Vaudois 151

Role of Poxvirus Vectors in the Development of an HIV Vaccine

3:54 p.m.  Selected Abstracts for Oral Presentation

Chairs:Michele La Placa, M.D. - University of Bologna and David Pauza - Institute of Human Virology

4:00 p.m. Roberto f Speck, Ph.D. - University Hospital of Zurich 152

TLR8 Triggering Induces HIV from Latently Infected Cells of MyeloidMonocytic Origin and Indirectly from Latently Infected CD4+ T Cells Via theMAPK Pathway and TNF-α Respectively

4:07 p.m. Fabio Romerio, Ph.D. - Institute of Human Virology 153

Modeling HIV-1 Latency in vitro

4:14 p.m. Massimiliano Secchi, Ph.D. - San Raffaele Scientific Institute 154

Anti-HIV-1 RANTES Derivatives Acting as CCR5 Antagonists Present Full Additivityor Synergy in Combination With Different Entry/Fusion Inhibitors

4:21 p.m. Elisa Saba, Ph.D. - San Raffaele Scientific Institute 155

HIV-1 Infection and Replication of Cervico-VaginalHistocultures

4:28 p.m.  Laurel Lagenaur, Ph.D. - National Cancer Institute 156

A Live Microbicide Shows Efficacy in a Repeated Low Dose Challenge Model

4:35 p.m. Donato Zipeto, Ph.D. - University of Verona 157

Fusion Complexes and CD-4 Independent Env for the Induction of BroadSpectrum Neutralizing Antibodies Against HIV-1

4:40 p.m.  ADJOURN

6:00 p.m. Aperitivo

8:30 p.m.  Historical Lecture with Regional Dance Performance

 (Coordinated by Arnaldo Caruso and Sebastiano Ando)

Location: Sunshine Club Hotel Ballroom

Speakers, participants, and guests are invited to attend.

Back to Top | Article Outline

Thursday, October 7, 2010

HIV Vaccine Part 4: Therapeutic Vaccines for HIV and Cancer

Chairs:Cornel Fraefel, Ph.D. - ATH University of Zurich and Giampiero Carosi, M.D. - University of Brescia

9:00 a.m. Arnaldo Caruso, M.D. - University of Brescia 158

HIV-1 Matrix Protein p17:A Candidate Antigen for Therapeutic VaccinesAgainst AIDS

9:18 a.m. Luigi Buonaguro, M. D. - Istituto Nazionale Tumori 159

Immune Signatures and Systems Biology of Vaccines

9:36 a.m. Jeffrey Schlom, Ph.D. - National Cancer Institute 160

Recombinant Vector-based Vaccines for Cancer Therapy

 Zwi Berneman, MD, Ph.D. - Antwerp University Hospital 161

Dentritic Cell Vaccination in Acute Myeloid Leukemia

9:54 a.m.  Daniel Zagury, M.D. - NEOVACS 162

Active Anti-IFN α Immnotherapy Applied to Chronic Viral and AutoimmuneDiseases

Back to Top | Article Outline

HIV Vaccine Part 5: Defining Targets for Protective Immunity

Chairs:Nelson L. Michael, M.D., Ph.D. - Walter Reed Army Institute of Research and Maria C. Re, Ph.D.

- University of Bologna

10:12 a.m.  Lucia Lopalco, Ph.D. - fondazione San Raffaele del Monte Tabor 163

New Immune Strategies to Reduce CCR5 Expression and Block HIV Infection

10:30 a.m.  Susan B. Zolla-Pazner, Ph.D. - NYU School of Medicine, Veterans Affairs Medical Center 164

Using Epitopes Recognized by Monoclonal Antibodies as Vaccine Templates

20 minutes BREAK

10:50 a.m.  Ben Berkhout, Ph.D. - University of Amsterdam 165

Reconsidering a Live-Attenuated HIV Vaccine?

11:08 a.m.  George Lewis, Ph.D. - Institute of Human Virology 166

Fc-Mediated Anti-HIV Effector Function Mediated by New MonoclonalAntibodies That Recognize Epitopes Selectively Exposed During Viral Entry

11:26 a.m.  David Montefiori, Ph.D. - duke University Medical Cente 167r

Magnitude and Breadth of the Neutralizing Antibody Response in RV144

Back to Top | Article Outline

HIV Vaccine Part 6: Lessons from Animal Models

Chairs:Maria Salvato, Ph.D. - Institute of Human Virology and Massimo Galli, M.D. - University of Milan

11:44 a.m. Anna Aldovini, M.D. - Children's Hospital Boston

SIVDNA/rMVA Nasal Vaccination Provides Better Control of Viremia andDisease Progression in Female than Male Macaques

12:02 p.m. Guido Silvestri, M.D. - University of Pennsylvania 169

SIV Infection of Natural Hosts

12:20 p.m.  Ruth Ruprecht, M.D., Ph.D. - Dana-Farber Cancer Institute

Recombinant Protein Immunogens: Protection Against R5 Clade C SHIVTransmission and Correlates of Protection

12:38 p.m. Christopher Miller, DVM, Ph.D. - California National Primate Research Center A Protective Live-attenuated AIDS Vaccine Suppresses Innate Immunity and Inflammation in Immunized Rhesus Macaques

Back to Top | Article Outline

HIV Clinical Science and Therapy

Chairs:Gioacchino Angarano, M.D. - University of Bari and Robert Redfield, M.D. - Institute of Human Virology

12:56 p.m. Introduction - Stefano Vella, M.D. - Istituto Superiore di Sanità

1:00 p.m. MarkWainberg, Ph.D.-McGill AIdS Centre 172

Monitoring HIV Drug Resistance as a Guide to Understanding Viral Pathogenesis

1:15 p.m. Giuseppe Tambussi, M.D. - San Raffaele Scientific Institute

Cytokine-based Therapy in HIV Infection: from IL-2 to IL-7

1:30 p.m.  LUNCH

3:00 p.m.  Antonella Castagna, M.D. - San Raffaele Hospital 174

Salvage Therapy in HIV-1Infected Patients

3:15 p.m. James Mullins, Ph.D.-University of Washington 175

HIV-1 Evolution in Primary Infection is Affected by Stochastic Followedby Selective Processes

3:30 p.m. Carl June, M.D. - University of Pennsylvania School of Medicine 176

Exploring the Potential of CCR5 and CXCR4 Modified CD4 T Cells toTarget the HIV-1 Reservoir

3:45 p.m.  BREAK

Back to Top | Article Outline

New Treatment Approaches to HIV Disease

Chairs:Roger Pomerantz, M.D. - Merck and Anita De Rossi, Ph.D. - University of Padua

4:00 p.m. Introduction: Roger Pomerantz, M.D. - Merck Is a Cure Possible for HIV Disease?

4:15 p.m. Anders Vahlne, M.D., Ph.D. - Karolinska Institutet 177

Peptide Linkers Between Natural Antibodies and HIV Targets

4:30 p.m. Robert Redfield, M.D. - Institute of Human Virology 178

Targeting Cell Cycle to Enhance the Potency of Antiretroviral Therapeutic Agents

4:45 p.m. Saverio Parisi, M.D. - University of Padua

Residual Viremia and HIV Compartmentalization in HAART Treated Patients

5:00 p.m. ADJOURN

Scintille Fashion Show - by invitation only

Back to Top | Article Outline

Friday, October 8, 2010

Some Infectious Causes or Possible Causes of Cancer

Chairs:Robert C. Gallo, M.D. - Institute of Human Virology and Kiyoshi Takatsuki, M.D., Ph.D. - Kumamoto

University School of Medicine

9:00 a.m.  Kiyoshi Takatsuki, M.D., Ph.D. - kumamoto University School of Medicine 180

Adult T-Cell Leukemia/Lymphoma in Japan: Reminiscences and Perspectives

9:18 a.m.  Kuan-Teh Jeang, M.D., Ph.D. - National Institutes of Health 181

HTLV-1 Research After Three Decades: Insights into Cellular TransformationMechanisms for ATL (Adult T-Cell Leukemia)

9:36 a.m. Toshiki Watanabe, M.D., Ph.D. - University of Tokyo 182

Risk Indicators for Disease Progression in Asymptomatic HTLV-1 Carriers:A Nationwide Prospective Study in Japan and Expression Profile AnalysisBased on the Material Bank

9:54 a.m.  Mark Kaplan, M.D.-University of Michigan Medical Center 183

HIV Exposes Major “Trafficking” in HERV-KHML-2 Viruses Which are Criticalto the Pathogenesis of HIV Infection and Lymphoma

10:12 a.m.  Reinhard kurth, Ph.D. - Robert koch Institute 184

Beneficial and Detrimental Effects of Human Endogenous Retroviruses (HERVs)

10:30 a.m.  David Markovitz, M.D. - University of Michigan 185

Do Modern Endogenous Retroviruses Still Replicate?

20 minutes BREAK

Back to Top | Article Outline

HIV-Associated Cancers

Chairs:Marvin Reitz, Ph.D. - Institute of Human Virology and Eva Klein, M.D. - Karolinska Institutet

11:10 a.m.  George klein, M.D., Ph.D. - karolinska Institutet 186

Awakening of Dormant Tumor Cells by Inflammation

11:28 a.m.  Dario Di Luca, M.D. - University of ferrara 187

KSHV, Angionesis and Kaposi Sarcoma

11:46 a.m.  Parkash Gill, M.D. - University of Southern California 188

VEGF-Notch-EphrinB2 Pathways in AIDS-Related Kaposi Sarcoma

12:04 p.m. James Goedert, M.D. - National Cancer Institute 189

HIVTropism and Decreased Risk of Breast Cancer

Back to Top | Article Outline

Tumor Growth and Inhibition

Chairs:Luigi Chieco-Bianchi, M.D. - University of Padua and Sebastiano Andò, M.D - University of


12:22 p.m. Wuyuan Lu, Ph.D. - Institute of Human Virology 190

Novel Classes of p53 Activators for Cancer Therapy

12:40 p.m. Eitan Yefenof, Ph.D. - The Hebrew University, Hadassah Medical School 191

Sensitizing Hemopoietic Malignant Cells to Glucocorticoid InducedApoptosis by PK Inhibitors

1:00 p.m.  LUNCH

2:30 p.m. Isaac Witz, Ph.D. - Tel Aviv University 192

Cross-Talk with the Microenvironment: The Case of Melanoma Brain Metastasis

2:48 p.m. Andrei kozlov, Ph.D. - St. Petersburg University 193

The Possible Evolutionary Role of Tumors in the Origin of New Cell Types

Back to Top | Article Outline

Selected Abstracts for Oral Presentation

Chairs:Guido Poli, M.D. - San Raffaele Scientific Institute and Mark Kaplan, M.D. - University of Michigan

Medical Center

3:06 p.m. Franco Buonaguro, M.D. - National Cancer Institute, Fond Pascale 194

HPV-Related Cancers in HIV-Infected Subjects

3:13 p.m. Sayed Abdelwahab, Ph.D. - Minia University 195

Hepatitis C Virus-Specific Immune Response Among Egyptian HealthcareWorkers at High Risk of Infection Without Viremia or Seroconversion

3:20 p.m. Jean Carr, Ph.D. - Institute of Human Virology 196

Newly Identified Circulating Recombinant Form Coming in Nigeria

3:27 p.m. Judith Torimiro, Ph.D.-Chantal Biya International Reference Centre 197

Population Level Drug Resistance in HIV Type 1 Protease and ReverseTranscriptase in Cameroon: 1995-2010 Review

3:39 p.m. Badran Bassam, Ph.D. - Institut Jules Bordet, Universite Libre de Bruxelles 198

Identification of a Human Natureal Regulatory T-Cell Micro-RNA Signatureand Demonstration of the Major Role Played by miR-31, miR-21 andValproate in Foxp3 Expression

3:46 p.m. Marco Rusnati, Ph.D. - University of Brescia 199

Role of Heparan Sulfate Proteoglycans in HIV-l Tat-InducedTransendothelial Migration of Lymphoid Cells

4:00 p.m.  ADJOURN

Copyright © 2011 Wolters Kluwer Health, Inc. All rights reserved.